Skip to content

Novel Organic Kale Products for Prevention of Obesity/Type 2 Diabetes

Novel Organic Kale Products for Prevention of Obesity/Type 2 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04298970
Enrollment
34
Registered
2020-03-06
Start date
2020-03-03
Completion date
2023-12-01
Last updated
2023-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes

Brief summary

Investigating the health beneficial effects of freeze-dried Brassica oleracea var. acephala with a high content of fibers, protein, vitamin, minerals, and secondary metabolites on patients with type 2 diabetes.

Interventions

DIETARY_SUPPLEMENTIntervention

Freeze-dried Brassica oleracea var. acephala

DIETARY_SUPPLEMENTPlacebo

Placebo product

Sponsors

Future Food Innovation
CollaboratorINDUSTRY
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Type 2 diabetes, dietary treatment and/or with oral anti-diabetics * Diabetes debut \> 30 year * Plasma fasting blood glucose \> 4mM and \< 12 mM * HbA1c \> 43 and ≤ 108 mmol/mol * BMI between 23-40 kg/m2 * Fasting triglyceride \> 1.7 mmol/L and HDL-cholesterol, men: \< 1.03 mmol/L and women: 1.29 mmol/L.

Exclusion criteria

* Participating or have been participating in other clinical trials within the last 2 months. * In treatment with insulin, systemic glucocorticoids, glitazones or GLP-1 analogs. * Cardiovascular-, physiological-, neurological-, and/or kidney diseases. * Alcohol- or pill abuse. * Acute diseases. * Blood pressure ≥ 160/100 * Pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frameDescription
iAUCThroughout the study (up to 1 year)The blood glucose incremental area under curve, OGTT

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026